NASDAQ: CGEMCullinan Therapeutics Inc Stock
$7.89+0.28 (+3.68%)
Updated Apr 17, 2025
CGEM Price
$7.89
Fair Value Price
N/A
Market Cap
$461.67M
52 Week Low
$6.85
52 Week High
$30.19
P/E
-2.84x
P/B
0.78x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$167.38M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$145M
Beta
1.27
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CGEM Overview
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CGEM's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CGEM
Ranked#354 of 463
Ranked#354 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important CGEM news, forecast changes, insider trades & much more!
CGEM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CGEM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGEM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CGEM is good value based on its book value relative to its share price (0.78x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
CGEM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CGEM due diligence checks available for Premium users.
Valuation
CGEM fair value
Fair Value of CGEM stock based on Discounted Cash Flow (DCF)
Price
$7.89
Fair Value
$2.28
Overvalued by
245.65%
CGEM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CGEM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.84x
Industry
-177.72x
Market
27.98x
CGEM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.78x
Industry
4.05x
CGEM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGEM's financial health
Profit margin
Revenue
$0.0
Net Income
-$47.6M
Profit Margin
0%
CGEM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$621.8M
Liabilities
$31.5M
Debt to equity
0.05
CGEM's short-term assets ($414.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGEM's short-term assets ($414.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGEM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CGEM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$36.6M
Investing
$16.0M
Financing
$1.6M
CGEM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CGEM vs Biotech Stocks
Cullinan Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.